// STATE LEGISLATION TRACKER

Minnesota HF 4057: Miscellaneous technical corrections to laws and statutes made; erroneous, obsolete, and omitted text and references corr

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Minnesota
Bill: HF 4057
Session: 2025-2026
Filed: 2026-03-09
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

HF4057 is a broad technical-corrections bill that cleans up obsolete, erroneous, or conflicting Minnesota statutory text. Based on the title, subjects, and status, it does not appear to target compounded peptides, off-label prescribing, telehealth, clinician scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No apparent change to compounded peptide access
No apparent new limits on off-label prescribing
No apparent telehealth or clinician-scope change
No apparent change to 503A or 503B compounding rules
No apparent controlled-substance or PDMP impact

What to Watch For

Note Technical-corrections bills can touch many statutes, but nothing in the title or subjects signals peptide-specific policy.

Note The House file was postponed after the identical Senate file moved forward, so track the enacted companion for final text.

Note Any peptide impact would likely be indirect and would need confirmation from the specific statutory sections amended.

Where the Bill Stands

HF4057 was indefinitely postponed because identical SF4244 was substituted, passed both chambers, and was signed as Chapter 88.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws